EP300 and cancer: To our knowledge, this is the first study that provides a mechanistic rationale for the development of p300/CBP degraders instead of the bromodomain inhibitors, which has direct implications for ongoing pharmacological and clinical efforts focused on targeting these enzymes in human cancers.